AveXis Inc. (NASDAQ:AVXS) has received an average rating of “Buy” from the six analysts that are covering the firm. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $47.00.

A number of equities analysts have recently weighed in on AVXS shares. Zacks Investment Research upgraded AveXis from a “hold” rating to a “buy” rating and set a $47.00 target price on the stock in a research note on Tuesday, August 16th. Jefferies Group upped their price objective on AveXis from $42.00 to $50.00 and gave the company a “buy” rating in a research note on Monday. Wells Fargo & Co. started coverage on AveXis in a research note on Friday, July 15th. They issued a “market perform” rating on the stock. Finally, Chardan Capital reiterated a “buy” rating and issued a $60.00 price objective on shares of AveXis in a research note on Friday, August 12th.

In other AveXis news, insider Paul B. Manning sold 289,855 shares of the business’s stock in a transaction on Tuesday, September 13th. The shares were sold at an average price of $34.50, for a total transaction of $9,999,997.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/avexis-inc-nasdaqavxs-given-consensus-rating-of-buy-by-analysts.html

A number of large investors have recently modified their holdings of the stock. Deerfield Management Co. acquired a new stake in shares of AveXis during the first quarter worth about $60,928,000. VHCP Management II LLC acquired a new stake in shares of AveXis during the first quarter worth about $24,501,000. RTW Investments LLC acquired a new stake in shares of AveXis during the first quarter worth about $12,895,000. FMR LLC boosted its stake in shares of AveXis by 212.8% in the second quarter. FMR LLC now owns 688,353 shares of the company’s stock worth $26,171,000 after buying an additional 468,279 shares during the last quarter. Finally, Franklin Resources Inc. acquired a new stake in shares of AveXis during the second quarter worth about $16,514,000. 54.46% of the stock is currently owned by institutional investors and hedge funds.

Shares of AveXis (NASDAQ:AVXS) traded down 4.345% during midday trading on Wednesday, hitting $42.815. The company’s stock had a trading volume of 502,270 shares. The stock’s 50 day moving average is $37.48 and its 200-day moving average is $34.03. AveXis has a 52-week low of $17.40 and a 52-week high of $47.76. The firm’s market cap is $985.30 million.

AveXis (NASDAQ:AVXS) last announced its earnings results on Thursday, August 11th. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.09. Equities analysts predict that AveXis will post ($3.35) EPS for the current fiscal year.

About AveXis

AveXis, Inc, formerly Biolife Cell Bank, Inc, is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

5 Day Chart for NASDAQ:AVXS

Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.